aTyr Pharma Inc (NASDAQ:LIFE) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.06.
Shares of aTyr Pharma (NASDAQ:LIFE) traded up 4.84% during midday trading on Friday, hitting $3.25. The stock had a trading volume of 7,467 shares. The stock’s market cap is $77.18 million. The firm’s 50-day moving average price is $3.27 and its 200-day moving average price is $3.13. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45.
Several equities research analysts have recently weighed in on the company. BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the company a “hold” rating in a research note on Saturday, March 18th. Citigroup Inc increased their price target on aTyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research note on Monday, March 20th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of aTyr Pharma in a research note on Saturday, March 18th.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.